Find Clinical Trials

Inclusion Criteria: * Diagnosed with type 2 diabetes per investigator discretion * No more than 20% of the sample will have A1c \< 7.5% (confirmed by medical record review or an A1c completed within 3 months of the screening visit) * Age ≥18 years and ≤ 80 years * Does not meet ADA guidelines for physical activity (\< 150 minutes of aerobic exercise per week defined as any activity where the participant can talk but not sing) * Has a smartphone compatible with a Fitbit Exclusion Criteria: * Completing more than 60 minutes of moderate to vigorous activity per week defined as activity where you cannot sing (moderate) or can't say more than a few words without gasping for breath (vigorous)(14) * Any medical condition which, in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders. * Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12- months * Any planned surgery during the study which could be considered major in the opinion of the investigator * Blood disorder or dyscrasia within 3 months before screening, or the use of hydroxyurea, which, in the investigator's opinion, could interfere with the determination of HbA1c * Has taken oral or injectable steroids within the past 8 weeks or plans to take oral or injectable steroids during the study, as they may interfere with the determination of HbA1c. * Planning to move from Colorado within 3 months * Current Pregnancy or planning on pregnancy in the next 3 months * Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision that impacts ability to see FitBit, impaired memory) * Unable to speak English as this is a small feasibility study that does not have the resources to adapt the intervention for Spanish * Current participation in another diabetes-related clinical trial

Inclusion Criteria: * Patients aged ≥ 18 years and ≤ 65 years. * Patient followed by a specialist in allergy and/or respiratory diseases working at one of the investigating sites in France. * Patient allergic to HDM and with a clinical history of HDM-allergic asthma. * Positive specific IgE (≥ 0.35 kUA/L, ImmunoCAP®) and positive skin prick test for Dermtophagoides pteronyssinus and/or Dermtophagoides farinae at screening. * Patients satisfying diagnostic criteria for severe asthma, according to GINA international guidelines. * A clinical history of asthma exacerbations in the past two years. * A history of at least 2 asthma exacerbations during the previous 12 months. * Uncontrolled asthma (ACT \<20/25) * Lung function measured by FEV1 ≥ 70% of predicted value or according to local requirements. * Patients with persistent severe asthma who meet the Marketing Authorization criteria for Tezspire® (Tezepelumab) and Acarizax® prescriptions. Exclusion Criteria: * Patients sensitized and regularly exposed to animal dander, molds, and/or cockroach or any another perennial allergen. * Patients treated with a monoclonal antibody for asthma within the previous 3 months or 5 half-lives. * Patients who have received Sublingual immunotherapy (SLIT) or Sub-Cutaneous Immunotherapy (SCIT) treatment with DermatophagoIdes pteronyssinus and/or Dermatophagoïdes farinae within the previous 5 years. * Patients received any education provided by a medical indoor environment counselor during the 12 months before the study, or and educational program is programmed during the study. * Patients with acute respiratory tract infections. * The patient who have performed any specific measure for mites' avoidance during the 12 months before the study or plan to implement such measures during the study. * Pregnant, breastfeeding or lactating women. * Patients with a history of tumor, autoimmune, or immune deficiency pathology. * Patients with hematological pathology (coagulation disorders, anemia) that could interfere with the blood test. * The patient reports any previous hypersensitivity reaction to the active substance or excipients present in Tezspire® or Acarizax®. * Patients unable to read and/or write French language. * Absence of signed consent. * Patients who are not beneficiaries of the French social security system. * Presence of any condition (physical, psychological or other) that might, in the investigator's opinion, hinder study performance. * The patient is unavailable or unwilling to participate in future visits or is unable to comply with trial protocol. * Women of childbearing potential and fertile men not using effective contraception. * The patient is participating in another study for asthma and/or allergy treatment. * Patients in an exclusion period determined by a previous study or is currently participating to any other allergy/asthma trial. * Patients under legal protection (guardianship or curatorship) * Patients with a business or personal relationship with trial staff or sponsor who is directly involved with the conduct of the trial.

Inclusion Criteria for patients: * Participants who are 21 years old and above. * Participants who self-reports to have hypertension for at least six months and/ or taking at least one type of antihypertensive medication daily for at least six months * Able to read English Exclusion Criteria for patients: * Participants with type 1/ type 2 or secondary diabetes mellitus * Participants with CKD stage 3B and above * Participants with serum potassium of above 4.5mmol/L (on the latest blood test) * Participants with serum sodium of less than 135 mmol/L (on the latest blood test) * Participants who are on daily potassium chloride * Participants who are on diuretics (thiazide or thiazide like diuretics) * Participants who are pregnant * Participants who had been diagnosed with any terminal illnesses, visually impaired, disability or mental health related illnesses (visually impaired refers to individuals who self-report to have difficulty reading the wordings on the patient consent form, even with the use of visual aids) * Participants who are not clinically stable (Clinically stable patients are defined in this study as: * Has clinic BP 100-160/60-100 mmHg, Heart Rate (HR) 60-100 bpm * No recent hospitalizations (within the last 3 months) due to hypertensive emergencies, strokes, myocardial infarctions or other acute cardiovascular events * No recent symptoms such as severe dizziness, fainting, or chest pain) \*Participants who are on PRN potassium supplements is not an exclusion criteria Inclusion criteria for Healthcare providers: * HCPs who had prior experience in advising patients on dietary salt reduction * HCPs who self-reported to have ever treated patients with hypertension Exclusion criteria for healthcare providers -nil

Inclusion Criteria: * Voluntary acceptance to participate in the study, * Being diagnosed with breast cancer and being in the patient group in which surgical operation is planned, * Not having participated in laughter yoga practice before, * Being literate, * Not having a psychiatric disease (diagnosis) * Not having a communication and understanding disability related to vision, hearing * Being in the age group of 18 and over Exclusion Criteria: * Not wanting to participate in the study, * Being in the patient group with a condition recommended not to do laughter yoga (having undergone surgery in the abdominal region in the last three months, uncontrolled hypertension, glaucoma, hernia, epilepsy), * Not having participated in any of the laughter yoga sessions, * Having physical restriction/respiratory problems and not being able to perform yoga movements.

Inclusion Criteria: * Subjects will be enrolled only when all the inclusion criteria are fully met. 1. Subjects who aged 19 to 80 years diagnosed with breast cancer through biopsy. 2. Subjects diagnosed with breast cancer who had both MRI and CT and ultrasound scans. 3. Patients diagnosed with breast cancer who are scheduled to undergo breast-conserving surgery, have not received neoadjuvant chemotherapy, and show no evidence of metastasis to other organs. 4. Tumor size criteria on ultrasound: : 5 mm ≤ tumor size ≤ 30 mm 5. Subjects whose biopsy pathology results are Invasive carcinoma. 6. Subjects who have a single lesion. 7. Subjects who have received a full explanation of the clinical trial fully understand its details, voluntarily decide to participate, and provide written informed consent. Exclusion Criteria: * Subjects will be excluded from enrollment if they meet any of the exclusion criteria. 1. Subjects prohibited from both MRI, CT and Ultrasound scans. 2. Subjects with no lesions visible on CT. 3. Pregnant or lactating(i.e., breastfeeding) subjects. 4. Subjects who are biologically male. 5. Subjects with breast cancer who received neoadjuvant chemotherapy or who have metastasized to other organs 6. Subjects whose biopsy pathology results are Invasive lobular carcinoma 7. Subjects deemed unsuitable for the study according to judgment of the investigator

Inclusion Criteria: Healthy Controls * • Aged 7-15 years, both sexes * No diagnosis of asthma in childhood * No inhaled asthma medication during the previous 2 years * No wheezing or shortness of breath during the previous 2 years * Written informed consent from the participant and guardian Inclusion Criteria: Children with Asthma * Aged 7-15 years, both sexes * Physician-diagnosed asthma (ICD-10 codes J45.0/J45.1/J45.9) * Inhaled corticosteroid treatment for at least 6 months * Either: * Well-controlled asthma (c-ACT/ACT score ≥20) and no clinical need to intensify medication, or * Poorly controlled asthma with physician-confirmed need for intensified asthma medication Exclusion Criteria: * • Premature birth before 32 gestational weeks * Other chronic cardiopulmonary or neurological conditions affecting airways (excluding asthma) * Severe underlying illness such as malignancy * Beta-blocker medication * Active immunological disease

Inclusion Criteria: * Women aged 18 years or older who were diagnosed with stage 0 to IV breast cancer. * Women undergoing chemotherapy (at least two cycles) or having completed it at least six months earlier. * Cognitive impairment must be reported, with scores below 54 on the FACT-Cog scale Exclusion Criteria: * Women with significant neurological conditions. * Women with psychiatric conditions. * Women with contraindications for physical exercise.

Inclusion Criteria: 1. Fully understand and comply with the requirements of this study, and voluntarily sign the informed consent form. 2. Female breast cancer patients aged ≥18 and ≤75 years, with histologically or cytologically confirmed recurrent or metastatic triple-negative breast cancer (TNBC) as defined by the latest ASCO/CAP guidelines (based on the most recent biopsy or other pathological specimens). 3. Have received at least 1 but no more than 2 prior lines of anti-tumor therapy （ Disease progression during or within 12 months after completing neoadjuvant/adjuvant therapy counts as one line of therapy；Must have received taxane-based therapy at any stage；A maximum of 1 prior antibody-drug conjugate (ADC) therapy is allowed.） 4. Documented homologous recombination repair deficiency (HRD) (BRCA1/2 mutation and/or HRD-positive status. 5. Any PD-L1 expression status (no restriction). 6. Have at least one measurable lesion according to RECIST 1.1 criteria (assessed by CT or MRI). Bone-only lesions are considered non-measurable and do not qualify for enrollment. 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 8. Availability of tumor tissue samples for biomarker testing. 9. Ability to swallow tablets normally. 10. Expected survival ≥3 months. 11. Presence of adequate bone marrow and organ function. Exclusion Criteria: 1. Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1, anti-CTLA-4) or PARP inhibitors (e.g., olaparib, niraparib). 2. Current use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (\>10 mg/day prednisone or equivalent) within 2 weeks prior to enrollment. 3. History of severe allergic reactions to monoclonal antibodies. 4. Discontinuation of prior anti-PD-1/PD-L1/CTLA-4 therapy due to immune-related toxicity. 5. Known history or evidence of interstitial lung disease or active non-infectious pneumonitis. 6. History of CNS metastases or current CNS metastases. Baseline imaging to confirm absence of brain metastases is not mandatory. Patients with unknown CNS status but clinical signs suggestive of CNS involvement are eligible if CNS metastases are ruled out by CT/MRI. 7. History of other malignancies (except non-melanoma skin cancer or carcinoma in situ of the cervix), unless disease-free for ≥3 years. 8. Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg) despite antihypertensive therapy. History of hypertensive crisis or hypertensive encephalopathy. 9. History of unstable angina, myocardial infarction, chronic heart failure (LVEF \<50%), or clinically significant arrhythmias requiring treatment (except stable atrial fibrillation) within 6 months prior to treatment. 10. Current therapeutic anticoagulation or thrombolysis (prophylactic low-dose aspirin/LMWH permitted). 11. Clinically significant effusions (pleural, peritoneal, or pericardial) requiring drainage, unless stabilized post-drainage per investigator assessment. 12. Arterial/venous thromboembolic events (e.g., CVA, TIA, DVT, PE) within 6 months prior to enrollment. 13. Major vascular disease (e.g., aortic aneurysm requiring repair or recent peripheral arterial thrombosis) within 6 months. 14. Major surgery within 4 weeks prior to treatment or anticipated during the study (excluding diagnostic procedures). 15. Urine protein ≥++ on dipstick with confirmed 24-hour urine protein \>1.0 g. 16. Prior radiotherapy (except palliative bone radiation), chemotherapy, or surgery (excluding biopsy) within 4 weeks before treatment initiation; \<4 weeks since last antibody therapy; \<5 half-lives since last targeted therapy (including investigational agents); or unresolved toxicities (\>CTCAE grade 1, except alopecia). 17. Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC \>15×10⁹/L. 18. Immunodeficiency (e.g., HIV); HBsAg-positive with HBV DNA ≥2000 IU/mL; or HCV antibody-positive. 19. Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma resolved without intervention, or stable hypothyroidism on hormone replacement. 20. Live vaccination within 4 weeks prior to treatment or planned during the study. 21. Planning pregnancy, pregnancy, or suckling period; 22. The investigator judged that the patients are not suitable for participating in this trial.

Inclusion Criteria: 1. Patients who are treated with at least one dose of tezepelumab according to the indication in the locally approved prescribing information 2. Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: 1. Other off-label indications according to the locally approved prescribing information 2. Current participation in any interventional trial

Inclusion Criteria : * Cis man, cis woman, trans man, trans woman or non-binary, * Aged 18 to 65 years old, * Meets the DSM-5 criteria for the diagnosis of moderate to severe EDC and is eligible for antidepressant treatment. Non-Inclusion Criteria : * Patients under guardianship or trusteeship, * Patients with schizophrenia according to DSM-5 criteria, * Patients who have received psychotropic treatment in the 5 days prior to inclusion (or 21 days for fluoxetine or aripiprazole), with the exception of benzodiazepines and hydroxyzine at the doses and in compliance with the indications of the Marketing Authorisations, * Patients with an unstable physiological state or a serious and symptomatic medical condition in the opinion of the investigator, * Pregnant or breast-feeding patients, * Patients with a known autoimmune disease, in particular Crohn's disease or thyroiditis, or any other pathology which could, in the opinion of the investigator, modify the blood concentration of immune biomarkers, * Patients unable to give informed consent to participate in the study or who cannot be given informed information, * Patients not covered by a social security scheme, * Patients participating in another interventional study on the day of inclusion, * Patients under court protection, * Patients vaccinated less than 30 days ago, * Patients with difficulties reading, understanding or speaking French. Exclusion Criteria : * Participants will have the right to withdraw their consent at any time for any reason whatsoever without any prejudice to them, * The investigator may prematurely exclude a subject from the study, in agreement with the sponsor, if the subject presents one or more exclusion criteria, * Diagnosis of schizophrenia during follow-up or any other diagnosis that would lead to a change in the initial EDC diagnosis, * Any condition or situation which, in the opinion of the investigator, would be incompatible with the continuation of the study or which would lead to a bias in the management of the data.

Inclusion Criteria: 1. willing and able to give written informed consent; 2. men or women, 25-55 years of age; 3. a primary diagnosis of DSM-V major depression, current, or Bipolar, depressed type as diagnosed by the SCID-V; 4. score of \>14 on the PHQ-9 from screening and HAM-D score ≥18 for study entry; 5. off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine), 6. CRP ≥3 mg/L, 7. PHQ-9 anhedonia score ≥2. Exclusion Criteria: 1. history or evidence (clinical and laboratory) of an autoimmune disorder 2. history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection; 3. history of any type of cancer requiring treatment with more than minor surgery; 4. unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing); 5. significant hematological abnormalities at screening (ANC \< 1500, Hgb\<10, platelet\< 100,000) 6. history of progressive multifocal leukoencephalopathy, 7. history of deep venous thrombosis, 8. history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK), 9. major surgery within 8 weeks prior to screening or will require major surgery during the study, 10. current or recent (\<4 weeks prior to randomization) viral (including COVID-19), bacterial, fungal, or parasitic infection or any other active or recent infection, 11. symptomatic herpes zoster infection at or within 12 weeks of randomization, 12. history of disseminated/complicated herpes zoster (for example, ophthalmic zoster or CNS involvement), 13. cirrhosis of the liver from any cause, 14. any of the following specific abnormalities on screening laboratory tests: ALT or AST \>2 x upper limits of normal (ULN), alkaline phosphatase (ALP) ≥2 x ULN, total bilirubin ≥1.5 x ULN (with the exception of patients on atazanavir, who must have total bilirubin \<2 x ULN), 15. chronic kidney disease with eGFR \<60 mL/min/1.73 m2, 16. history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; substance abuse/dependence within 6 months of study entry (as determined by standardized clinician interview); 17. active suicidal plan as determined by a score \>3 on item #3 on the HAM-D; g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms); 18. history of a cognitive disorder or traumatic head injury involving loss of consciousness; 19. pregnancy or lactation, 20. use of gender affirming hormone therapy; 21. chronic use of non-steroidal anti-inflammatory agents (NSAIDS) (excluding 81mg of aspirin), immunosuppressive (e.g., biologics), glucocorticoid containing medications or minocycline within 6 months, or non-prescription supplements with known or suspected anti-inflammatory properties (e.g. fish oil supplements) within 2 weeks of baseline, or at any time during the study; 22. any contraindication for MRI scanning; 23. failure of more than 2 antidepressant trials (at least 6 weeks at recommended dose) in the current episode or 5 antidepressant trials lifetime; and 24. BMI \>45 (to exclude severe obesity) or at the PI's discretion based on the patient's ability to fit comfortably in the MRI scanner.

Inclusion Criteria: 1. Subjects who voluntarily participates in the trial and signs the informed consent form (ICF); 2. Male or female subjects, aged between 18 and 65 years (inclusive) at the time of signing ICF; 3. Subjects whose HAMD-17 score ≥18 during the screening and baseline periods; 4. Subjects who meet the diagnostic criteria for depressive disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5), without psychotic symptoms; 5. Subjects whose Clinical Global Impressions-Severity (CGI-S) scores ≥4 during the screening and baseline periods; 6. Subjects who agree to discontinue the use of other antidepressants, anxiolytics, antipsychotics, mood stabilizers, benzodiazepine sedative-hypnotics, etc., except those specified in the study protocol during the treatment period; Subjects with reproductive potential (including spouses of male subjects) must have no plans for pregnancy or sperm donation from the screening period until 6 months after the last dose and must be willing to use at least one effective contraceptive method (such as abstinence, condoms, etc., as detailed in Section 5.3). Exclusion Criteria: 1. Presence of any medical condition that may interfere with the participation in the trial, including but not limited to the following: history of malignant tumors, history of epilepsy or complications, hemolytic anemia, pulmonary embolism, or respiratory depression; 2. Within 6 months prior to screening, occurrence of congestive heart failure classified as New York Heart Association (NYHA) Class III or higher, unstable angina, acute myocardial infarction, hemorrhagic stroke (stroke), or ischemic stroke (including transient ischemic attack); or undergoing percutaneous coronary intervention, coronary artery bypass grafting, cardiac valve repair/replacement; or presence of severe arrhythmia as determined by the investigator at screening; 3. A personal or family history of long QT syndrome, a family history of sudden death in first-degree relatives (parents, offspring, and siblings) before the age of 40; and/or a personal history of unexplained syncope within 1 year prior to screening; and/or QTcF \>450 ms (male) or QTcF \>470 ms (female) based on resting ECG results at screening; 4. Patients with uncontrolled hypertension at screening, defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg (checked prior to randomization); 5. Subjects with clinically significant hepatic impairment, defined as total bilirubin (TBIL) \>2× the upper limit of normal (ULN) or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2×ULN; 6. Subjects with clinically significant renal impairment (creatinine clearance \[Ccr\] \<30 mL/min). The Ccr calculation formula is provided in Note b. 7. Subjects with history of any psychiatric disorders other than DSM-5 depressive disorder, including but not limited to: bipolar and related disorders, obsessive-compulsive and related disorders, trauma- and stressor-related disorders, schizophrenia, anxiety disorders, sleep-wake disorders, substance-related and addictive disorders, or depressive episodes secondary to other psychiatric or somatic conditions; 8. Subjects whose HAMD-17 score at baseline shows a reduction ≥25% compared to the screening period. 9. Subjects at risk of suicide: Those who have exhibited suicidal behavior (including actual attempts, interrupted attempts, or failed attempts) within 1 year prior to the first dose, or subjects with a score ≥3 on item 3 (SUICIDE) of the HAMD-17 scale at screening or baseline, or a 'yes' response to items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation, or subjects with a history of suicidal intent/self mutilation behavior during the current depressive episode; 10. Subjects with history or current episode of failure to respond to two adequate courses of antidepressant treatment; 11. Subjects who are receiving systemic psychotherapy (interpersonal therapy, psychodynamic therapy, cognitive behavioral therapy, etc.), music therapy, exercise therapy, acupuncture, or other treatments during screening and/or at baseline, and who will continue to require these treatments during this study period; 12. Subjects who have received electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), light therapy, etc., within 3 months prior to screening, or are considered by the investigator to currently require such treatment; 13. Subjects who discontinued psychotropic medications less than 5 half-lives before randomization (at least 2 weeks for monoamine oxidase inhibitors and at least 4 weeks for fluoxetine); 14. Subjects with history of severe allergies, or known hypersensitivity/allergic reaction or intolerance to any component of the investigational drug; 15. Subjects with evidence of alcohol abuse (average weekly consumption ≥14 units of alcohol, where 1 unit ≈ 360 mL of beer, 45 mL of spirits, or 150 mL of wine) or alcohol dependence within the 6 months prior to screening, which the investigator considers may interfere with the subject's understanding or completion of the trial; 16. Subjects with history of drug dependence/drug abuse within the past 1 year; 17. Subjects with history of hepatitis B, or positive hepatitis B virus surface antigen (HBsAg) at screening, or positive hepatitis C virus (HCV) antibody, or positive Human immunodeficiency virus (HIV) antibody, or positive treponema pallidum antibody; 18. Subjects who participated in a clinical trial involving the administration of investigational drugs (new chemical entities), devices, or surgical procedures within 3 months or 5 half-lives (whichever is longer) prior to screening; 19. Females with positive pregnancy test during screening or baseline visits, females who are pregnant, breastfeeding, or planning to become pregnant during the trial, or males or females of childbearing potential unwilling to use effective contraception within 6 months after the last dose; 20. Subjects who are unable to swallow medications, or as judged by the investigator, have any condition that may significantly affect drug absorption, distribution, metabolism, and excretion (such as active intestinal disease, partial or complete intestinal obstruction, chronic diarrhea, etc.), or any condition that may pose a hazard to the participating subjects; 21. Subjects with history of organ transplantation (excluding corneal transplantation); 22. Subjects who donated blood or experienced blood loss ≥400 mL, or received blood transfusion within 3 months prior to screening; 23. Subjects with poor compliance or other reasons that make the subject unsuitable for participation in this trial, as judged by the investigator.

Inclusion Criteria: 1. women aged 18-70 years 2. The primary breast lesion was confirmed as invasive breast cancer by core needle biopsy 3. Axillary lymph node metastasis confirmed by fine needle aspiration or core needle biopsy 4. plan to undergo neoadjuvant chemotherapy 5. operable breast cancer 6. Patients with good heart, lung, liver, and kidney function are suitable for surgery 7. Informed consent Exclusion Criteria: 1. Surgery is not planned or impossible 2. Metastasis of supraclavicular lymph nodes 3. distant metastasis, excluding bone metastasis 4. previous ipsilateral axillary surgery or radiotherapy 5. Due to personal or family factors, the patient is unable to cooperate with the surgical treatment recommended by the doctor according to the condition (breast conserving surgery or radical surgery). 6. Patients with severe heart and lung diseases, uncontrolled infectious diseases and other non-tumor related diseases could not tolerate comprehensive treatment such as surgery and chemotherapy 7. Unable to sign the informed consent form due to mental illness or other reasons 8. Poor medical compliance, and the study group believed that the patients could not complete the trial treatment process and follow-up according to the standard

Inclusion Criteria: * 1.Age ≥18 years, regardless of gender. 2.Clinically diagnosed with type 2 diabetes mellitus (per the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus \[2020 Edition\]). 3.Deemed suitable by the investigator for treatment with proline-containing gliflozin tablets (Hui You Jing) and being prescribed this medication for the first time. 4.Availability of glycated hemoglobin (HbA1c) test results within 4 weeks prior to enrollment. 5.Voluntary participation with signed informed consent. Exclusion Criteria: \- 1.History of moderate to severe renal impairment (eGFR \<30 mL/min/1.73 m²), end-stage renal disease, or dialysis. 2.Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Severe allergy to gliflozin or any excipient of the study drug. 3.Current or recent (within 1 month) participation in any other clinical trial. 4.Investigator judgment of unsuitability for the study.

Inclusion Criteria: 1. Diagnosed with Insomnia Disorder according to DSM-5 criteria, with a duration of at least 3 months. 2. Pittsburgh Sleep Quality Index (PSQI) total score \> 5. 3. Age 8 years or older. 4. Educational level of at least junior high school. 5. Voluntarily agree to participate and provide written informed consent. 6. Presence of depressive symptoms, defined as Hamilton Depression Scale (HAMD) score ≥ 16. Exclusion Criteria: 1. Presence of severe physical illnesses or major psychiatric disorders, or at risk of suicide. 2. Diagnosed or suspected of having sleep breathing disorders, restless legs syndrome, circadian rhythm sleep disorders, or engaged in shift work. 3. Pregnant or breastfeeding women. 4. Currently undergoing any psychological therapy.

Inclusion Criteria: 1. Chinese, aged 12-19 years old; 2. Written informed assent/consent of participation into the study is given by the participant and his/her parent or guardian (for those aged under 18), respectively; 3. Having a DSM-5 diagnosis of unipolar non-seasonal depression as confirmed by the Chinese version of the Kiddie-Schedule for Affective Disorders and Schizophrenia (K-SADS) psychiatric interview, DSM-5 Seasonal specifier, AND having a score on Children's Depression Rating Scale (CDRS-R) at least 40; 4. Being classified as evening chronotype according to the score on the reduced Horne-Östberg Morning-Eveningness Questionnaire (rMEQ), i.e. \<12. Exclusion Criteria: 1. A current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia spectrum disorders, organic mental disorders, or intellectual disabilities; 2. Having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt) as assessed by K-SADS; 3. Having been enrolled in any other clinical trial investigational products within one month at the entry of the study; 4. Initiation of or change in antidepressant medication within past 4 weeks; 5. Having been or is currently receiving any structured psychotherapy; 6. With hearing or speech deficit; 7. Night shift worker; 8. Trans-meridian flight across at least two time zones in the past 3 months and during the study; 9. Presence of an eye disease, e.g., retinal blindness, severe cataract, glaucoma.

Inclusion Criteria: 1. Females ≥18 yrs old 2. Pathologically confirmed HER2-positive advanced breast cancer; 3. Newly diagnosed brain metastes,At least one measurable intracranial lesion 4. Not received any systemic treatment for advanced stage 5. Radiotherapy was allowed in patients with an urgent need for control of intracranial symptoms 6. Adequate function of major organs 7. Willing to join in this study, able to provide written informed consent, good compliance and willing to cooperate with follow-up. Exclusion Criteria: 1.Has leptomeningeal metastasis or cystic metastatic lesions confirmed by MRI or lumbar puncture; 2.Existence of third space fluid (e.g. massive ascites, pleural effusion, pericardial effusion) that is not well controlled by effective methods, e.g. drainage; 3.Has received whole brain radiotherapy, chemotherapy, surgery within 2 weeks before first dose of study therapy; 4.Has known clinically significant lung disease, that is, moderate-to-severe lung disease which severely affects respiratory function, including but not limited to: idiopathic pulmonary fibrosis, pneumonitis. Prior ≥ grade 3 interstitial lung disease is not allowed to enrolment; 5.Has received full-dose anticoagulants or thrombolytics within 10 days before enrolment, or non-steroid anti-inflammatory drugs with platelet inhibition 6.Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor; 7.Participated in other drug clinical trials within 4 weeks before admission; 8.Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years. \-

Inclusion Criteria: Age ≥ 18 years * Self-reports as Black, Asian, Hispanic/Latin, ethnically originating from the Mediterranean rim or Pacific rim, or she/he tans easily in the sun * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Appendix 1, Section 18) * Attestation by the patient that she/he is not pregnant, lactating, or planning to become pregnant, or planning to father a baby during the study period * Histologic confirmation of breast malignancy (with TNM staging) If the patient did not receive adjuvant chemotherapy, adjuvant radiation must start within 180 days of lumpectomy or mastectomy. If the patient received adjuvant chemotherapy, adjuvant radiation should start within 60 days of the last dose of chemotherapy * Treatment plan includes one of the following: * Conventionally fractionated whole breast radiation (45-50 Gray in 25 fractions) * Moderately hypofractionated whole breast radiation (42.56 Gray in 16 fractions or 40 Gray in 15 fractions) * Conventionally fractionated chest wall radiation (45-50 Gray in 25 fractions) * Partial breast radiation (42.56 Gray in 16 fractions, 40 Gray in 15 fractions, or 30 Gray in 5 fractions) if using 3D conformal radiation or if the tumor is located close to the skin surface * Treatment of the regional lymph nodes, a tumor bed boost (4-8 fractions), and use of tissue-equivalent bolus on the chest wall may be included at the discretion of the treating physician. * Radiation will be photon-based. Note: If the patient receives a boost, photons and/or electrons may be used at the discretion of the treating physician. Exclusion Criteria: * Prior radiotherapy to any portion of the planned treatment site * Current inflammatory breast cancer or gross dermal involvement at initiation of radiotherapy * Concomitant immunotherapy or cytotoxic chemotherapy. Concomitant HER2 directed therapy or concomitant endocrine therapy is allowed * Active rash or dermatitis within the treatment field, or a history of any rash or dermatologic condition within the treatment field * Active collagen vascular diseases (ie lupus erythematosus, scleroderma, dermatomyositis) * History of organ transplant or bone marrow transplant * History of hypersensitivity or allergic reaction to any ingredients in the topical azelaic acid formulation * Has used within 28 days prior to baseline: * topical retinoids to the breast * oral retinoids * systemic (oral or injectable) antibiotics known to have an impact on the severity of skin rash or sun-sensitivity (eg, containing tetracycline and its derivatives, erythromycin and its derivatives, sulfamethoxazole, or trimethoprim) * systemic corticosteroids or immunosuppressive drugs, except as part of standard chemotherapy treatment or used for an IV contrast allergy * Has used on treated breast within 2 weeks prior to baseline: * topical corticosteroids * topical antibiotics * topical medications for skin rash (eg, metronidazole, azelaic acid) * Radiation therapy will be proton therapy or carbon therapy * External beam partial breast irradiation, brachytherapy partial breast irradiation, or intraoperative radiation are included in the treatment plan Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Inclusion Criteria: * Age ≥ 18 years. * History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise. * Body mass index (BMI) ≥ 35 kg/m\^2 at screening with a current diagnosis of at least 1 of the weigh-related comorbidities specified in the Japan Society for the Study of Obesity (JASSO) guideline OR BMI ≥ 27 kg/m\^2 to \< 35 kg/m\^2 at screening, with a current diagnosis of at least 2 of the weight-related comorbidities specified in the JASSO guideline. * For both BMI categories, at least 1 of the weight-related comorbidities must be hypertension, dyslipidemia, or T2DM according to the definitions below: 1. hypertension: treated, or with SBP ≥ 140 mmHg, or DBP ≥ 90 mmHg at screening. 2. dyslipidemia: treated, or with LDL \> 140 mg/dL (3.6 mmol/L), or triglycerides ≥ 150 mg/dL (1.7 mmol/L), or non-HDL cholesterol \> 170 mg/dL (4.4 mmol/L) or HDL \< 40 mg/dL (1.0 mmol/L) at screening. 3. T2DM: diagnosed ≥ 180 days before screening, and treated with diet and exercise alone and/or a stable treatment for at least 90 days before screening with up to 3 oral glucose-lowering medications (as per local labeling) (except for glucagon-like peptide-1 receptor agonists \[GLP-1RA\] and dipeptidyl peptidase-4 \[DPP-4\] inhibitors), and have a HbA1c ≥ 7% and ≤ 10% (53-86 mmol/mol) at screening. * In the opinion of the investigator, well-motivated and willing to: 1. Follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice, maintain a study log(s)/diary(ies), and complete required study visits and questionnaires. 2. Perform self-monitoring blood glucose (SMBG) per protocol (only for participants with T2DM). Exclusion Criteria: * Obesity induced by other endocrinological disorders or monogenetic or syndromic forms of obesity. * Self-reported change in body weight \> 5 kg within 90 days before screening. * Previous or planned (during the study) surgical, endoscopic, or device-based treatment for obesity. * For participants without diabetes at screening, type 1 or 2 diabetes mellitus or any other types of diabetes mellitus (except history of gestational diabetes). * For participants with T2DM at screening, any other type(s) of diabetes mellitus except T2DM. * History of chronic pancreatitis or history of acute pancreatitis within 180 days before screening. * Family (first-degree relative\[s\]) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2). * History of unstable major depressive disorder (MDD) or other severe psychiatric disorder within 2 years before screening. * Lifetime history of suicide attempt.

Inclusion Criteria: * Studying at Aydın Adnan Menderes University Söke Health Services College, * Taking the body mechanics course, * Being between the ages of 18-49, * Being able to read, speak and understand Turkish. Exclusion Criteria: * Having received physical therapy services due to musculoskeletal diseases in the last 3 months, * Having musculoskeletal diseases such as ankylosing spondylitis, chronic or structural joint diseases, * Having congenital malpositions of the musculoskeletal system, * Having a physical disability, * Having undergone artificial joint replacement, * Having multiple sclerosis, myodystrophic or other neurodegenerative diseases, Having serious diseases such as acute herniated disc, Using muscle relaxants or other drugs that affect muscle elasticity, Having a cardiovascular disease, Having a history of previous back surgery, Having a traffic accident in the last 6 months, Not being within the age range determined for the study, Having a mental disability that prevents answering the comprehension and evaluation forms.